Advertisement


Ethan M. Basch, MD, on Symptom Control and Quality: The Patient’s Voice

2017 Quality Care Symposium

Advertisement

Ethan M. Basch, MD, of The University of North Carolina at Chapel Hill, discusses programs—now rolling out at various institutions—that use direct patient reporting of symptoms as a part of quality assessment (Posters 61, 81; Abstract 218).



Related Videos

Issues in Oncology

Greg D. Judy, MD, on Safety Incidents in Radiotherapy

Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.

Issues in Oncology

Blase N. Polite, MD, MPP: The Oncology Care Model in Academia

Blase N. Polite, MD, MPP, of the University of Chicago, discusses implementing the Oncology Care Model in an academic health center and the challenges of getting buy-in from faculty members.

Breast Cancer
Survivorship

Nicole Mittmann, PhD, on Breast Cancer Well Follow-up

Nicole Mittmann, PhD, of the Sunnybrook Health Sciences Centre, discusses her study findings on transitioning breast cancer survivors to primary care and the savings in resources and dollars that accrued as a result (Abstract 1).

Issues in Oncology

Julie Bryar Porter, MS, on Improving Care: One Center’s Experience

Julie Bryar Porter, MS, of Stanford Health Care, discusses an approach to improving patient care with physician-led quality measures from diagnosis through end of life implemented at her academic cancer center (Abstract 49).

Issues in Oncology
Lung Cancer

Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)

Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).

Advertisement

Advertisement




Advertisement